Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes

  • Mark W. Julian,

    Affiliation Dorothy M. Davis Heart and Lung Research Institute, Division of Pulmonary Allergy, Critical Care, and Sleep Medicine, Wexner Medical Center, Columbus, OH, United States of America

  • Heather R. Strange,

    Affiliation College of Veterinary Medicine, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States of America

  • Megan N. Ballinger,

    Affiliation Dorothy M. Davis Heart and Lung Research Institute, Division of Pulmonary Allergy, Critical Care, and Sleep Medicine, Wexner Medical Center, Columbus, OH, United States of America

  • Richard S. Hotchkiss,

    Affiliation Departments of Anesthesiology, Medicine and Surgery, Washington University School of Medicine, St. Louis, MO, United States of America

  • Tracey L. Papenfuss,

    Affiliation College of Veterinary Medicine, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States of America

  • Elliott D. Crouser

    Elliott.Crouser@osumc.edu

    Affiliation Dorothy M. Davis Heart and Lung Research Institute, Division of Pulmonary Allergy, Critical Care, and Sleep Medicine, Wexner Medical Center, Columbus, OH, United States of America

Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes

  • Mark W. Julian, 
  • Heather R. Strange, 
  • Megan N. Ballinger, 
  • Richard S. Hotchkiss, 
  • Tracey L. Papenfuss, 
  • Elliott D. Crouser
PLOS
x

Abstract

Objective

Immune suppression during critical illness predisposes to serious infections. We sought to determine the mechanisms regulating tolerance and cross-tolerance to common pro-inflammatory danger signals in a model that recapitulates the intact in vivo immune response.

Materials and Methods

Flt3-expanded splenocytes obtained from wild-type or matching IRAK-M knockout (IRAK-M-/-), C57BL/6, male mice (8–10 weeks old) were treated repeatedly or alternately with either LPS or CpGA DNA, agonists of Toll-like receptor (TLR)-4 and -9, respectively, over successive 24-hour periods. Supernatants were collected following each 24-hour period with cytokine release (ELISA) and splenocyte IRAK-M expression (Western blot) determined. Tolerance and cross-tolerance were assessed in the absence or presence of programmed death receptor (PD)-1 blocking antibody or IL-7 pre-treatment.

Main Results

Splenocytes notably exhibited both tolerance and cross-tolerance to subsequent treatments with either LPS or CpGA DNA. The character of tolerance and cross-tolerance in this model was distinct following initial LPS or CpGA treatment in that TNFα and IFNγ release (not IL-10) were suppressed following LPS; whereas, initial CpGA treatment suppressed TNFα, IFNγ and IL-10 release in response to subsequent stimulation (LPS or CpGA). Tolerance and cross-tolerance were unrelated to IL-10 release or PD-1 but were attenuated in IRAK-M-/- splenocytes. IL-7 significantly suppressed IRAK-M expression and restored TNFα and IFNγ production without influencing IL-10 release.

Conclusions

In summary, acute immune tolerance and cross-tolerance in response to LPS or CpGA were distinct in that LPS selectively suppressed pro-inflammatory cytokine responses; whereas, CpGA suppressed both pro- and anti-inflammatory responses. The induction of tolerance and cross-tolerance in response to common danger signals was mechanistically unrelated to IL-10 or PD-1 but was directly influenced by IRAK-M expression. IL-7 reduced IRAK-M expression and attenuated immune tolerance induced by either LPS or CpGA, and thus may be useful for reversal of immune tolerance in the setting of critical illness.

Introduction

Tolerance in the setting of immune responses refers to a state of refractoriness towards a second stimulation by an immunostimulatory agent. The most extensively studied example of immune tolerance is in response to lipopolysaccharide (LPS), a component of Gram-negative bacteria which promotes immune cell signal transduction through Toll-like receptor (TLR)-4, wherein low-level pre-treatment with LPS is shown to induce hyporesponsiveness to subsequent LPS exposure in vitro [1] and in vivo [24]. LPS also promotes cross-tolerance to CpG- containing DNA [5], which is a putative immunostimulatory component of common DNA-viruses [(e.g., adenovirus, parvovirus, herpes simplex virus (HSV), and cytomegalovirus (CMV)] and mitochondrial DNA that is recognized by TLR-9 [611].

The mechanisms underlying tolerance induction and sustained cellular hyporesponsiveness remain unclear. Reductionist models (e.g., cell lines, immune cell isolates) fail to replicate in vivo immune tolerance and cross-tolerance. For example, CpG DNA treatment of RAW264.7 macrophages induces cross-tolerance to subsequent challenge by LPS [12]. In contrast, low-dose CpG DNA pre-treatment in vivo selectively protects against subsequent CpG DNA challenge and paradoxically enhances TNFα production and organ damage in response to subsequent LPS challenge [5]. Whereas alterations of several critical signal transduction pathways, particularly those regulated by IRAK-1 and IRAK-M, are implicated in the induction of immune cell tolerance [13, 14], the situation is likely to be much more complex in vivo. The intact immune response depends upon interactions among multiple cell types, and immune tolerance in vivo is potentially influenced by direct intercellular interactions, including inhibitory effects of programmed death receptor-1 (PD-1) and programmed death-ligand 1 (PD-L1) [15], and indirect suppression of nearby and remote immune cells by immune-modulating cytokines (e.g., TGFβ, IL-10) [16, 17]. Moreover, the mechanisms of immune tolerance may be further influenced by regional variables, including the variation of the immune cell populations within each tissue [18].

Immune tolerance has very significant implications in the context of critical illness. Critical illness associated with severe bacterial or viral infections (i.e., severe sepsis) or extensive trauma is characterized by an initial systemic pro-inflammatory response and subsequent immune suppression during which the host becomes susceptible to otherwise non-pathogenic microorganisms and activation of latent infections. Tolerance in the setting of critical illness is demonstrated in many cells, including cells that promote innate (e.g., macrophages) and adaptive (e.g., dendritic and T cells) immune responses, which explains susceptibility to an array of secondary infections and reactivation of latent infections [19, 20]. These secondary infections, and flaring of latent infections, contribute significantly to morbidity and mortality in the ICU setting [2022]. An emerging body of evidence further indicates that treatments directed at reversing manifestations of immune tolerance, particularly T cell “exhaustion” consequent to enhanced expression of programmed cell death (PD-1) and PD-ligand 1 (PD-L1) and the related suppression of monocyte responsiveness, as reflected by reduced TNFα production, may be of significant benefit in terms of preventing secondary infections in the context of critical illness [2022]. In this regard, IL-7, which potentiates T cell functions, is shown to reverse immune suppression in the context of severe sepsis [23].

We hypothesized that a murine splenocyte model would provide novel insights into the mechanisms by which LPS and CpG DNA induced tolerance and cross-tolerance, and that this model would be useful for exploring the means by which immune tolerance could be reversed. As hypothesized, these studies provide novel insight into the pathogenesis of immune suppression in the setting of acute critical illness, and provide support for the use of IL-7 to modulate tolerance and cross-tolerance under these conditions.

Materials and Methods

Ethics Statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by The Ohio State University Institutional Laboratory Animal Care and Use Committee (Approval Number: 2012000000197A). All efforts were made to minimize suffering, and tissue harvest was carried out immediately after approved euthanasia (70% carbon dioxide asphyxiation and cervical dislocation).

Reagents

Murine CpG-containing oligonucleotide, type A (CpGA, TLR-9 ligand) was obtained from InvivoGen (San Diego, CA). Lipopolysaccharide (LPS, from E. coli Serotype 0111:B4) was acquired from Alexis Biochemicals (Enzo Life Sciences, Inc.; Farmingdale, NY). The rat, anti-mouse, polyclonal programmed death receptor-1 (PD-1) blocking antibody (RMP1-14) and corresponding isotypic control (PD-1C, RTK2758) antibody were obtained from BioLegend (San Diego, CA). Recombinant human IL-7 was provided by Cytheris SA (Rockville, MD). The primary antibody to interleukin-1 receptor-associated kinase 3 (IRAK-M) was acquired from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) with the corresponding secondary antibody attained from Cell Signaling Technology, Inc. (Danvers, MA). Mouse splenocytes (see below) were cultured using RPMI 1640 media (Life Technologies; Grand Island, NY). Unless otherwise stated, all additional chemicals were obtained from Sigma-Aldrich Corp. (St. Louis, MO) using the best available grade.

Mouse pDC Expansion and Splenocyte Preparation

Eight-to-ten-week old, adult, male, C57BL/6 mice (~25 g) (The Jackson Laboratory; Bar Harbor, ME) (n = 14) were employed for in vivo pDC expansion and the subsequent source for all splenocytes. Additional corresponding experiments, however, utilized pDC-expanded splenocytes obtained similarly from matching IRAK-M knockout (IRAK-M-/-) mice (n = 3). pDC expansion was carried out using melanoma cells [expressing murine (Flt3)] as previously described [24, 25]. Briefly, 4 × 106 B16 melanoma cells (C57BL/6 background), transfected with mouse recombinant Flt3 ligand (Flt3L) cDNA using an MFG-retroviral vector, were suspended in sterile saline and injected subcutaneously in two sites over both flanks. Mice were euthanized when the tumor size reached ~1–1.5 cm in diameter (after 3–4 weeks), and the spleens were harvested. Elevated pDC populations following Flt3L-induced expansion were confirmed via flow cytometry following immunofluorescent staining of splenocytes with a mouse anti-plasmacytoid dendritic cell antigen 1 (mPDCA-1)-FITC (JF05-1C2.4.1, Miltenyi Biotec, Inc.; Auburn, CA) antibody [11].

In previous studies [11, 26], we found that splenocytes obtained from normal, healthy untreated mice have unpredictable responses to murine CpGA DNA, presumably related to varying immature dendritic cell populations, even in littermates. Use of Flt3 ligand (Flt3L) expanded the immature dendritic cell populations (particularly pDCs) within the spleen, such that we were able to achieve highly uniform responses to TLR-9 ligands. Given the high cost of Flt3L, injection of species-matched B16 melanoma cells transfected with Flt3L served as a safe and inexpensive way to expose the bone marrow to Flt3L and achieve the desired effect, nearly doubling their presence in the total cell population within the spleen from 1–2% to ~4% after a 2–3 week exposure during tumor growth. Taking great care to obtain the spleen in advance of any negative effects of the abdominal tumor, the end result of this was to provide a splenocyte population that responded strongly and consistently to minimal to moderate doses of CpGA DNA across all cell preparations, enabling investigation of TLR-9 mediated immune responses. Since it was our intent to provide a model of an intact in vivo immune cell population that demonstrated tolerance/cross-tolerance to CpGA DNA, it became necessary to first establish one that would respond vigorously and consistently to CpGA DNA upon initial treatment.

Single cell splenocyte suspensions were prepared following mechanical disaggregation of the spleen tissue and gently passing the released cells and tissue fragments through a 70 μm nylon cell strainer. Following erythrocyte lysis, cells were washed and then suspended in RPMI 1640 (supplemented with 25 mM HEPES, 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, and 10% FBS) (Life Technologies). Cells were then cultured in 48-well plates at a concentration of 1 × 106/ml in the above media with only 2% FBS at 37°C in a 5% CO2-humidified atmosphere. After ~1 hour, desired concentrations of murine CpGA DNA (1 μM), LPS (10 ng/ml) or volume-matched vehicle (PBS) were then added to the medium. The cell supernatants were then carefully collected (minimizing cell disruption) at ~24 hours post-treatment and stored at -80°C for later analyses. The adherent cells were gently washed with pre-warmed PBS (~100 μl) and then cultured again as stated above in supplemented RPMI with 2% FBS. Following an additional hour for equilibration, subsequent additions of CpGA DNA, LPS or PBS were added to the medium as before providing matching or all cross-treatment combinations. All pre-incubations with PD-1 or PD-1C blocking antibodies (5 μg/ml) or recombinant human IL-7 (25 ng/ml) were made as a one-time dose 30 minutes prior to the aforementioned subsequent 24-hour ligand additions. Once again, cell supernatants were carefully collected after an additional 24 hours post-treatment and stored as before. Similar experiments involving successive matching and cross-treatment combinations of CpGA DNA, LPS or PBS, as described above, with or without IL-7 pre-treatment were carried out in Flt3L-expanded mouse splenocytes isolated from matching IRAK-M knockout (IRAK-M-/-) mice wherein IRAK-M depletion was confirmed as detailed previously [27, 28].

Flow Cytometry Analysis

Following the treatment combinations identified above over 48 hours, splenocytes were collected and washed twice in cold FACS buffer. Cells were evaluated by three-color flow cytometry using a combination of the following directly conjugated antibodies (clones): PD-1 (CD279) (J43) or PD-L1 (CD274) (MIH5), CD11b (M1/70), CD11c (HL3), CD3 (17A2), CD4 (GK1.5), CD8a (53–6.7) and CD19 (1D3) (BD Biosciences; San Jose, CA), and PDCA-1 (JF05-1C2.4.1) (Miltenyi Biotec, Inc.; San Diego, CA) or the appropriate directly conjugated isotype controls for 20 minutes in the dark at 4°C. Cells were then washed twice in FACS buffer and re-suspended in 300 μl of FACS buffer for flow cytometry analysis. All flow samples were processed on an Accuri C6 flow cytometer, and the results analyzed using Accuri C6 software (BD Biosciences).

Cytokine Measurements

Mouse splenocyte supernatants, collected at ~24 hours subsequent to each treatment series (i.e., at both 24 and 48 hours post-initial treatment), were analyzed for their IFNγ, TNFα (eBioscience, Inc.; San Diego, CA) and IL-10 (BD Biosciences; San Diego, CA) concentrations by ELISA according to the manufacturer’s recommendations. Cytokine ELISA sensitivities were 15, 8 and 16 pg/ml respectively.

IRAK-M Signaling in Mouse Splenocytes

In some instances, mouse splenocytes were cultured and treated similarly in 6-well plates to provide enough cells for later Western blot analyses. Cells receiving matching treatments over the first and second 24-hour periods with and without intervening IL-7 pre-treatment at 24 hours post-treatment were collected after the entire 48-hour experiment and processed with added protease inhibitors for Western blot analyses according to standard techniques. IRAK-M expression in mouse splenocytes was then determined by employing a rat, anti-mouse polyclonal primary antibody (1:1000). Given that both β-actin and GAPDH protein expressions were observed to increase with treatment, protein band densities corresponding to IRAK-M expression were normalized to protein load established by parallel use of silver-stained gels (Pierce silver stain kit, Thermo Fisher Scientific; Rockford, IL) [29] and then compared to corresponding bands from untreated cells.

Statistical Analyses

The data was derived from independent experiments, as designated in the figure legends, and was expressed as mean SD, and statistical significance was based upon a value of p ≤ 0.05. SigmaPlot 12.0 and SYSTAT 13.0 software were used to plot the data and carry out the statistical analyses, respectively. Splenocyte cytokine release in response to various treatment combinations over time (devised to identify tolerance/cross-tolerance) was compared to that from untreated controls (Vehicle, Vehicle) using the Kruskal-Wallis test. Where appropriate, post hoc analyses between group rank means were performed using Dunn’s test. Additional comparisons between experimental groups and corresponding untreated controls involving pre-treatment inhibition studies (i.e., PD-1 blocking antibody, IL-7) designed to potentially influence tolerance/cross-tolerance, use of IRAK-M-/- splenocytes intended to evaluate the role of IRAK-M in tolerance/cross-tolerance, and flow cytometry analyses of PD-1 and PD-L1 expression and Western blot evaluation of IRAK-M expression following splenocyte activation were performed using the Wilcoxon Rank-Sum test.

Results

Post-Treatment Characterization of Splenocyte Populations Demonstrated Similar Cell Viability

Knowing that cell death occurs in splenocyte populations over time which can be affected by factors such as cell stimulation and given our desired focus on the post-treatment period wherein tolerance/cross-tolerance can occur, we evaluated our experimental preparations for their total protein concentration as a reflection of the total splenocyte viability after the first 24-hour treatment period and following the removal of all non-viable cells by washing (see Methods). Thus, the total protein concentration was reflective of the total viable splenocyte population. The total protein concentration post-treatment was 112.8 ± 2.9 following CpGA treatment and 110.3 ± 3.6 following LPS treatment as a percentage of that for the control (vehicle-treated) group (100.0 ± 5.7) (NS). IL-7 pre-treatment yielded similar findings when compared to treatment alone: 118.2 ± 2.9 for IL-7 + CpGA (p < 0.05), and 107.2 ± 3.2 for IL-7 + LPS (NS). The small but statistically significant increase in total splenocyte protein concentrations following CpGA treatment in the presence of IL-7 may be related to its known effects on immune cell turnover, including reduced immune cell apoptosis and enhanced proliferation [30, 31]. These findings demonstrated that the total splenocyte viability was very similar among the groups allowing for comparative analyses during the post-treatment-induced tolerance/cross-tolerance period.

LPS Tolerance Selectively Related to Pro-Inflammatory Cytokines

LPS treatment of cultured splenocytes resulted in near complete tolerance to subsequent LPS treatment 24 hours later, as reflected by dramatically suppressed TNFα release (Fig 1A). Notably, LPS induced sustained IFNγ release which extended to 48 hours in subsequently untreated cells, and this sustained IFNγ release was observed to be nearly identical to that following successive LPS treatment-induced tolerance (Fig 1B). Finally, LPS did not induce any IL-10 release (Fig 1C). As such, IL-10 cannot be implicated in the induction of tolerance to LPS.

thumbnail
Fig 1. Repeated exposure to TLR-4 ligand, LPS, induces tolerance to splenocyte pro-inflammatory cytokine release.

The presented data was derived from at least 4 independent experiments, each in triplicate. (A) LPS (10 ng/ml) induced significant TNFα release from cultured Flt3L-expanded mouse splenocytes (1 × 106 cells/ml) 24 hours post-treatment. In response to a subsequent LPS treatment, TNFα release was dramatically reduced 24 hours later. (B) Similarly, significant splenocyte IFNγ release was observed 24 hours following LPS treatment. IFNγ release was markedly decreased 24 hours after a successive LPS treatment. This release, however, was very similar to the sustained IFNγ release observed over the subsequent 24-hour period in the absence of follow-up treatment (LPS, Vehicle). (C) Splenocytes failed to demonstrate any IL-10 release in response to LPS treatment [*p < 0.01, relative to time-matched untreated (Vehicle, Vehicle) controls; p < 0.01, compared to the associated LPS treatment group at 24 hours (LPS, LPS) and the time-matched LPS treatment alone group (Vehicle, LPS), and p < 0.01, relative to the time-matched untreated (Vehicle, Vehicle) control and the associated LPS treatment group at 24 hours (LPS, Vehicle)].

https://doi.org/10.1371/journal.pone.0132921.g001

CpG DNA Tolerance Non-Selectively Influenced Both Pro- and Anti-Inflammatory Cytokines

CpGA DNA treatment of cultured splenocytes resulted in tolerance to subsequent CpGA DNA treatment. Like LPS tolerance, CpGA DNA treatment strongly suppressed TNFα release to a subsequent CpGA DNA treatment (Fig 2A). Moreover, IFNγ release following CpGA DNA treatment, as with LPS, was sustained for at least 48 hours and was observed to be quite similar to that following successive CpGA DNA treatment-induced tolerance (Fig 2B). Unlike the situation with LPS treatment but as was observed with IFNγ release in this setting, IL-10 release following CpGA DNA treatment was sustained for at least 48 hours which was not different from that resulting from a tolerance-induced secondary exposure to CpGA DNA (Fig 2C).

thumbnail
Fig 2. Tolerance to splenocyte cytokine release results from repeated exposures to TLR-9 ligand, CpGA DNA.

The presented data was derived from at least 4 independent experiments, each in triplicate. (A) 24 hours post-treatment, CpGA DNA (1 μM) significantly induced Flt3L-expanded mouse splenocyte (1 × 106 cells/ml) TNFα release. This effect was notably attenuated 24 hours after subsequent treatment with CpGA DNA. (B) Likewise, splenocyte exposure to CpGA DNA yielded marked release of IFNγ by 24 hours post-treatment. Successive treatment with CpGA DNA resulted in a significant reduction in IFNγ release which was observed to be comparable to the sustained IFNγ release typically demonstrated during the subsequent 24 hours when untreated (CpGA, Vehicle). (C) Splenocyte IL-10 release in response to repeated treatments with CpGA DNA yielded a pattern similar to that observed with IFNγ release [*p < 0.01, compared to time-matched untreated (Vehicle, Vehicle) controls; p < 0.05, relative to the associated CpGA treatment group at 24 hours (CpGA, CpGA) and the time-matched CpGA treatment alone group (Vehicle, CpGA); p < 0.01, compared to the time-matched untreated (Vehicle, Vehicle) control and the associated CpGA treatment group at 24 hours (CpGA, Vehicle), and §p < 0.01, relative to the associated CpGA treatment group at 24 hours (CpGA, CpGA) only].

https://doi.org/10.1371/journal.pone.0132921.g002

LPS and CpG DNA Cross-Tolerance Were Not the Same

LPS treatment of cultured splenocytes resulted in cross-tolerance to subsequent CpGA DNA treatment. CpGA DNA treatment 24 hours after LPS exposure resulted in significant suppression of both TNFα (Fig 3A) and IFNγ (Fig 3B) release, which was more dramatic for TNFα. LPS exposure also attenuated IL-10 release in response to subsequent CpGA DNA treatment (Fig 3C).

thumbnail
Fig 3. Cross-tolerance to splenocyte cytokine release results from Sequential exposures to LPS followed by CpGA DNA.

The presented data was derived from at least 4 independent experiments, each in triplicate. (A) Flt3L-expanded splenocyte (1 × 106 cells/ml) TNFα release was dramatically diminished 24 hours following treatment with CpGA DNA (1 μM) after a prior 24-hour exposure to LPS (10 ng/ml). (B) Similarly, following a previous 24-hour exposure to LPS, splenocyte IFNγ release was significantly suppressed 24 hours after treatment with CpGA DNA. (C) Consistently, splenocyte IL-10 release demonstrated the same pattern of cross-tolerance in response to CpGA DNA at 24 hours post-treatment after an earlier 24-hour exposure to LPS [*p < 0.01, compared to time-matched untreated (Vehicle, Vehicle) controls; p < 0.05, relative to the time-matched CpGA treatment alone group (Vehicle, CpGA), and p < 0.01, compared to the time-matched untreated (Vehicle, Vehicle) control and the associated LPS treatment group at 24 hours (LPS, Vehicle)].

https://doi.org/10.1371/journal.pone.0132921.g003

CpGA DNA treatment of cultured splenocytes resulted in selective cross-tolerance to subsequent LPS treatment for TNFα and IFNγ, but not IL-10. As was the case for cross-tolerance induced by LPS, initial exposure to CpGA DNA resulted in suppression of TNFα (Fig 4A) and IFNγ (Fig 4B) following subsequent treatment with LPS. However, it was interesting to note that CpGA DNA treatment actually primed splenocytes for the production of IL-10 following subsequent exposure to LPS (Fig 4C).

thumbnail
Fig 4. Sequential exposures to CpGA DNA followed by LPS lead to cross-tolerance to splenocyte cytokine release.

The presented data was derived from at least 4 independent experiments, each in triplicate. (A) Following a prior 24-hour exposure to CpGA DNA (1 μM), TNFα release from Flt3L-expanded mouse splenocytes (1 × 106 cells/ml) was significantly reduced 24 hours after subsequent treatment with LPS (10 ng/ml). (B) Likewise, splenocyte IFNγ release was markedly diminished 24 hours after treatment with LPS following a previous 24-hour exposure to CpGA DNA. (C) Surprisingly, splenocyte IL-10 release was significantly and notably augmented in response to LPS at 24 hours post-treatment after an earlier 24-hour exposure to CpGA DNA [*p < 0.01, relative to time-matched untreated (Vehicle, Vehicle) controls; p < 0.05, compared to the time-matched LPS treatment alone group (Vehicle, LPS), and p < 0.01, relative to the time-matched untreated (Vehicle, Vehicle) control and the associated CpGA treatment group at 24 hours (CpGA, Vehicle)].

https://doi.org/10.1371/journal.pone.0132921.g004

PD-1/PD-L1 Did Not Influence Immune Tolerance within 48 hours of LPS or CpG DNA Treatment

PD-1/PD-L1 expression was promoted in both monocyte/macrophage lineage cells and T cell lineage cells (Fig 5B and 5C, respectively) in response to either LPS or CpGA DNA. Notably, the percentage of cells expressing PD-L1 was nearly 4 times greater than for PD-1-expressing cells (Fig 5). Of note in this regard, splenocytes are a heterogeneous population of cells, and the slight variability in the side scattered light (SSC) is considered to be due to specific populations responding to the activation stimuli (and resultant enhanced expression of PD-1/PD-L1). Activation of cells, particularly myeloid cells, can change the internal composition/granularity/complexity within these cells and/or induce some degree of proliferation which will result in an increased SSC and signal variability (see S1 Fig). Despite the observed induction of PD-1, anti-PD-1 pre-treatment had no effect upon tolerance or cross-tolerance in response to treatment with either CpGA DNA or LPS (Fig 6).

thumbnail
Fig 5. Splenocyte membrane expressions of both PD-1 and PD-L1 increase following TLR-4/TLR-9 stimulation.

The presented data was derived from at least 3 independent experiments. Data represents the percentage of grouped splenocyte populations demonstrating both PD-1 and PD-L1 membrane expression by flow cytometry analysis 48 hours after successive 24-hour exposures to the ligand treatment combinations detailed on the X-axis. (A) Representative flow cytometry scatter plots demonstrating that the percentage of both PD-1- and PD-L1-expressing splenocytes increased after successive stimulation with either LPS or CpGA DNA compared to Vehicle, Vehicle (Veh, Veh)-treated controls. (B) Both PD-1 (left) and PD-L1 (right) membrane expression levels were significantly increased in monocytes and dendritic cells after either LPS or CpGA DNA exposure. (C) Likewise, following either LPS or CpGA DNA treatment, T cells demonstrated elevated membrane expression levels of both PD-1 (left) and PD-L1 (right) identical to those observed in the monocytes/dendritic cells [PD-1 expression: *p < 0.05, compared to the untreated (Vehicle, Vehicle) control group (white bar); PD-L1 expression: *p < 0.05, relative to the untreated (Vehicle, Vehicle) control group (white bar). Following an initial given treatment (i.e., LPS or CpGA DNA), there was no statistical difference among the 3 secondary treatment groups (shaded bars) for either PD-1 (left) or PD-L1 (right).].

https://doi.org/10.1371/journal.pone.0132921.g005

thumbnail
Fig 6. Tolerance and cross-tolerance to splenocyte cytokine release is unaffected by blocking PD-1.

The presented data was derived from at least 3 independent experiments, each in triplicate. Data represents splenocyte cytokine release 48 hours after successive 24-hour exposures to the ligand treatment combinations detailed on the X-axis. (A) Pre-treatment (30 minutes) of Flt3L-expanded splenocytes (1 × 106 cells/ml) with an mouse anti-PD-1 blocking antibody (or corresponding isotypic control antibody, PD-1C) (5 μg/ml) prior to the secondary 24-hour ligand treatment had no effect upon resultant TNFα release regardless of the treatment combination employed. (B) Similarly, anti-PD-1 pre-treatment did not alter resultant splenocyte IFNγ release for any of the treatment combinations used. (C) Consistently, resultant splenocyte IL-10 release was unaffected for all treatment combinations by anti-PD-1 pre-treatment.

https://doi.org/10.1371/journal.pone.0132921.g006

IL-7 Attenuated Tolerance and Cross-Tolerance to LPS and CpG DNA

Although dramatic tolerance/cross-tolerance had been observed in most settings for all cytokines evaluated, IL-7 pre-treatment was observed to particularly improve responsiveness in terms of TNFα release only in the setting of successive CpGA DNA treatments, though significant tolerance remained (Fig 7A). However, IL-7 pre-treatment markedly suppressed tolerance and cross-tolerance to both LPS and CpG DNA in terms of IFNγ responses (Fig 7B), which was in keeping with the established T cell stimulatory effects of IL-7 [21]. Notably, IL-7 did not significantly reverse tolerance or cross-tolerance in terms of IL-10 release (Fig 7C), the implications of which are discussed below.

thumbnail
Fig 7. IL-7 pre-treatment restores responsiveness to subsequent ligand exposures attenuating tolerance and cross-tolerance.

The presented data was derived from at least 3 independent experiments, each in triplicate. Data represents splenocyte cytokine release (as a percent of the matching no tolerance/cross-tolerance [i.e., (Vehicle, LPS) or (Vehicle, CpGA), respectively] secondary ligand exposure alone) 48 hours after successive 24-hour exposures to the ligand treatment combinations detailed on the X-axis. (A) Following a 24-hour exposure to CpGA DNA (1 μM), pre-treatment (30 minutes) of Flt3L-expanded mouse splenocytes (1 × 106 cells/ml) with human recombinant IL-7 (25 ng/ml) prior to the subsequent ligand treatment significantly improved responsiveness to CpGA DNA-induced TNFα release 24 hours post-treatment. (B) Regardless of the treatment combination employed, tolerance and cross-tolerance to splenocyte IFNγ release in response to the secondary ligand exposure was attenuated by IL-7 pre-treatment. (C) Pre-treatment with IL-7 had no significant effect upon splenocyte IL-10 release resulting from the secondary ligand exposure [*p < 0.05, compared to the matching secondary treatment alone (white bar)].

https://doi.org/10.1371/journal.pone.0132921.g007

IRAK-M Mediated Tolerance and Cross-Tolerance to LPS and CpG DNA

Given the putative role of IRAK-M, a natural negative regulator of TRAF6/IRAK-1 and downstream NF-κB signaling, in the development of tolerance to TLR stimuli, including TLR-4 and TLR-9 [27], we sought to determine whether IRAK-M expression was essential for the induction of immune tolerance in the splenocyte culture model. As illustrated in Fig 8, splenocytes derived from IRAK-M-/- mice released significantly more TNFα compared to matching wild-type splenocytes in response to repeated treatments with CpGA DNA (Fig 8A) and comparatively higher levels of IFNγ in response to any combination of LPS and CpGA DNA treatments (Fig 8B). Interestingly, IRAK-M-/- mice had suppressed IL-10 release following successive treatments with CpGA DNA and LPS (Fig 8C). We then sought to determine whether IL-7 influenced IRAK-M expression during tolerance to LPS and CpGA DNA in the splenocyte culture model. As demonstrated in Fig 9, IL-7 significantly reduced IRAK-M expression during LPS-induced tolerance but did not significantly affect IRAK-M expression during CpGA DNA-induced tolerance (though improving TNFα responsiveness to repeated CpGA DNA treatments, Fig 8A).

thumbnail
Fig 8. IRAK-M-/- splenocytes demonstrate diminished tolerance and cross-tolerance through improved responsiveness to subsequent ligand exposures.

The presented data was derived from at least 3 independent experiments, each in triplicate. Data represents splenocyte cytokine release [as a percent of secondary ligand exposure in matching wild-type (WT) splenocytes] 48 hours after successive 24-hour exposures to the ligand treatment combinations detailed on the X-axis. (A) Following a 24-hour exposure to CpGA DNA (1 μM), Flt3L-expanded mouse IRAK-M-/- splenocytes (1 × 106 cells/ml) showed significantly improved responsiveness to subsequent CpGA DNA-induced TNFα release at 24 hours post-treatment which was further augmented by IL-7 (25 ng/ml) pre-treatment (30 minutes). (B) Regardless of the treatment combination employed, tolerance and cross-tolerance to IRAK-M-/- splenocyte IFNγ release in response to the secondary ligand exposure was significantly attenuated. This observation was unaffected by IL-7 pre-treatment. (C) IRAK-M-/- splenocytes demonstrated no enhancement in IL-10 responsiveness to the secondary ligand exposure regardless of IL-7 pre-treatment [*p < 0.01, relative to the matching wild-type secondary treatment (white bar), and p < 0.01, compared to the matching CpGA DNA secondary treatment in the absence of IL-7 (black bar)].

https://doi.org/10.1371/journal.pone.0132921.g008

thumbnail
Fig 9. Elevated splenocyte IRAK-M expression in response to repeated TLR-4 or TLR-9 ligand exposures is suppressed by IL-7 pre-treatment.

The presented data is representative of at least 3 independent experiments. (A) Representative photomicrograph of a Western blot demonstrating the changes observed in IRAK-M expression 48 hours after successive 24-hour repeated ligand exposures (with or without a 30 minute IL-7 pre-treatment). (B) Relative band density of splenocyte IRAK-M expression was dramatically elevated for both successive treatment combinations and notably reduced with intervening IL-7 pre-treatment [*p < 0.05, relative to the untreated (Vehicle, Vehicle) control group, and p < 0.05, compared to the corresponding LPS treatment combination in the absence of IL-7 (LPS, LPS)].

https://doi.org/10.1371/journal.pone.0132921.g009

Discussion

This study explores the mechanisms of tolerance and cross-tolerance in a splenocyte culture model that closely approximates the complex immune cell interactions in vivo. In an effort to more accurately model conditions observed in acutely ill patients (e.g., with severe bacterial or viral infections), this model was modified such that the initial doses of LPS and CpGA DNA used to induce tolerance were sufficient to produce an acute, intense immune response, such as occurs in the setting of severe acute illness [32, 33]. The profound tolerance and cross-tolerance observed in the splenocyte culture model is comparable to the results of previous studies conducted on isolated macrophage preparations [1, 34] and in humans treated with LPS [15] and is in keeping with tolerance observed in animal sepsis models [3] and in patients with severe sepsis and trauma [3537]. These observations, and the mechanisms considered herein, are highly relevant and have important implications for the development of secondary infections, including nosocomial bacterial infections and reactivation of latent viral infections, in the context of critical illness [2022].

As expected based upon studies performed on immortalized macrophage cell lines [1, 27] and in mice [38], high-dose LPS treatment of murine splenocytes promoted significant tolerance to subsequent LPS treatment and cross-tolerance to subsequent CpGA DNA treatment. Highly purified LPS, as was used in these experiments, is a selective TLR-4 agonist, a receptor that is essential for the host defense against Gram-negative bacterial infections [39, 40]. Moreover, tolerance and cross-tolerance induced by LPS non-selectively suppressed pro- and anti-inflammatory cytokine release, as previously reported following human endotoxemia [2, 4]. Compared to immortalized cell lines or single cell cultures, this model more closely replicates conditions of severe bacterial sepsis or trauma wherein the initial immune response is characteristically very intense (e.g., described as a “cytokine storm”) [32, 33]. In this regard, it is important to note that profound tolerance and cross-tolerance to high-dose LPS was established quickly (within 24 hours), as was previously reported in humans [41]. It follows that the stage is rapidly set for secondary bacterial, viral and fungal infections and reactivation of latent viruses, which contribute significantly to patient morbidity and mortality in critically ill patients [22].

Comparatively less is known about tolerance and cross-tolerance following CpG DNA exposure, which promotes both pro- and anti-inflammatory cytokine release via TLR-9 signaling. Like LPS, high-dose CpGA DNA exposure strongly induced tolerance to subsequent CpGA DNA or LPS treatment, particularly in terms of pro-inflammatory cytokine release. Unexpectedly, secondary exposure to LPS following CpGA DNA treatment led to the selective release of significant amounts of IL-10. To the extent that the splenocyte culture model reflects conditions in vivo, this finding suggests that a secondary Gram-negative bacterial infection following exposure to CpG DNA (e.g., DNA virus infection, or mitochondrial DNA release following trauma) could lead to further suppression of the immune response. This mechanism may contribute to the observed predisposition for bacterial super-infections following DNA viral infections [42, 43].

In terms of mechanisms by which immune tolerance is promoted within a mixed population of immune cells in the spleen, extracellular factors would seem to be the most plausible explanation. IL-10 is implicated as an important mediator of immune tolerance to LPS [44, 45]. IL-10 is also implicated in the development of secondary bacterial infections following viral infections [46] or trauma [47], conditions associated with TLR-9 activation [4850]. However, our data did not support a primary role of IL-10 in the development of tolerance or cross-tolerance in the spleen in response to LPS or CpGA DNA. For instance, no IL-10 was produced in response to the initial dose of LPS after which profound tolerance and cross-tolerance was observed (Fig 1C) and had no correlation with TNFα or IFNγ responses to CpGA DNA (Fig 2). That said, it is interesting to note that initial CpGA DNA treatment primed the splenocytes for IL-10 release following subsequent LPS exposure (Fig 4C). This finding implies that sequential TLR-9 and TLR-4 stimulation are additive in terms of promoting immune suppression.

Programmed death receptor-1 (PD-1) is another well-characterized mediator of immune tolerance and is shown to suppress immune responses to LPS in the RAW264.7 macrophage cell line [51]. Thus, it is not unexpected that PD-1 and PD-L1 expressions were significantly promoted by treatment combinations of LPS or CpGA DNA with successive challenges of either vehicle, LPS or CpGA DNA (Fig 5). Of note, baseline PD-L1 expression was much higher in both monocyte and T cell lineage cells within the splenocyte preparation compared to that of PD-1. In contrast to immune suppression during established sepsis, wherein PD-1/PD-L1 interactions between antigen-presenting cells and T cells are shown to strongly influence immune hyporesponsiveness [5254], anti-PD-1 antibody treatment did not influence LPS- or CpGA DNA-induced tolerance or cross-tolerance in the splenocyte model (Fig 6). Our findings are consistent with previous studies showing PD-1 to be expressed minimally on resting T cells compared to activated T cells wherein PD-1 is inducibly expressed and is functional within 24 hours with maximal expression occurring after 48 hours [55]. Since this study was limited to tolerance induced within 24 hours and given that expression levels were increasing significantly at that time, it remains plausible that PD-1/PD-L1 interactions could contribute to tolerance and cross-tolerance, especially relating to T cell functions (e.g., IFNγ release), that typically occurs several days after TLR-4 or TLR-9 activation.

In keeping with its documented capacity to promote dendritic cell-mediated T cell activation [56] and restoration of T cell responses (e.g., IFNγ) in the setting of sepsis [30], IL-7 treatment selectively restored IFNγ release in response to tolerance and cross-tolerance following treatment with high doses of either LPS or CpGA DNA (Fig 7B). T cells are particularly responsive to IL-7 given that their basal NF-κB activity plays an important role in enhancing their sensitivity to IL-7, even in the absence of antigen encounter, thus promoting T cell viability and responsiveness [57]. Restoration of T cell dysfunction, particularly IFNγ production, is shown to be critical for the resolution of infections during critical illness, as reflected by recent laboratory [53] and human studies [4, 58]. IL-7 also partially restored responsiveness in the form of TNFα release to CpGA DNA, a selective TLR-9 agonist (Fig 7A). This data indicates that the function of TLR-9-responsive splenocytes, particularly dendritic cells, is augmented by IL-7 in the setting of CpG DNA-mediated tolerance. With regard to restoring immune responsiveness in the setting of tolerance and cross-tolerance, it is important to note that IL-7 does not promote IL-10 release, which would potentially counterbalance the restoration of pro-inflammatory cytokines, including IFNγ and TNFα.

The likely role of IRAK-M, a putative mediator of LPS-induced tolerance [13, 59], in the induction of tolerance and the reversal thereof by IL-7 was supported to some degree by our data. IRAK-M is an endogenous negative regulator of TRAF6/IRAK-1 and downstream NF-κB signaling that is induced by LPS [27, 38] and by CpG DNA [60]. As demonstrated in Fig 8, splenocytes from IRAK-M-/- mice exhibited significantly less tolerance and cross-tolerance for certain immune responses, particularly TNFα release following successive treatments with TLR-9 agonist, CpGA DNA, and IFNγ (presumably T cell-mediated) release in response to any serial treatment combination of TLR-4 and TLR-9 agonists. The role of IRAK-M during tolerance was further supported by the observed induction of IRAK-M protein expression in the splenocyte model following either LPS or CpGA DNA treatment (Fig 9). IL-7 significantly but incompletely suppressed IRAK-M expression following LPS treatment, but had no significant effect following CpGA DNA treatment (Fig 9B). It is notable that other intracellular mechanisms are proposed to regulate tolerance and cross-tolerance following TLR stimulation, including endogenous negative regulators (e.g., SHIP-1, A20) [38], and microRNA-mediated inhibition of components of the MyD88-dependent signaling pathway [61, 62]. In fact, Zhou et al recently demonstrated that through its association with MyD88 and IRAK-4, IRAK-M mediates TLR-induced MEKK3-dependent secondary activation of NF-κB to produce the aforementioned inhibitory regulators, including SOCS1 and IκBα, as well as exacting an inhibitory effect upon the translational control of microRNA-mediated cytokine production and resultant inflammation [14]. These mechanisms appear to be most relevant to the suppression of monocyte/macrophage cell lines, which could account for the suppression of TNFα [61, 62] and perhaps IFNγ [41] in the current study. With respect to TLR-4 tolerance in particular, SHIP is known to contribute to LPS tolerance through the inhibition of NF-κB [63], and SOCS-1 regulates LPS responses through inhibition of JAK-STAT pathways [64]. Additional experiments are required to clarify these and alternate mechanisms by which tolerance and cross-tolerance in macrophage/dendritic cell lineages (e.g., blunted TNFα responses) and T cells (e.g., reduced IFNγ and IL-10 responses) occur in the setting of complex immune cell interactions, such as modeled herein and as occurs in vivo during critical illness.

Any attempt to model the immune response can be criticized; however, the ex vivo splenocyte culture model is considered to be a useful surrogate for complex in vivo immune responses in the setting of bacterial [6567] and viral infections [68, 69], and “sterile” immune responses to endogenous danger signals [11, 26]. The complex interaction among the various immune cells and the changes in immune cell function following stimulation in the splenocyte model recapitulates the dynamic immune cell interactions and related disease mechanisms in vivo. The tradeoff of a complex model is the inability to clearly define mechanisms, such as the source of a given cytokine, or the immune cell that is responding to a specific treatment (e.g., IL-7). That said, we can glean mechanisms based upon the known functions of the cells that are present in the modified (Flt3-expanded) splenocyte preparations (e.g., immature dendritic cells primarily respond to TLR-9 agonists and are unresponsive to TLR-4 in splenocyte cultures [70], T cells are the primary source of IFNγ, and dendritic cells and T cells produce IL-10 [71]) and the treatments (e.g., IL-7 promotes dendritic cell and T cell activation [20]; whereas, PD-1/PD-L1 regulates T cell activation by antigen-presenting cells [5254]). Admittedly, the immune response is complex and involves multiple cells and many intercellular interactions. In particular, NK cells are important participants in the immune response, particularly as a source of IFNγ, respond to both TLR-4 and TLR-9 agonists, and are rendered tolerant in response to activation by TLR agonists in the spleen. Recent studies indicate that regulatory T cells are critical for NK cell tolerance in the spleen under these conditions [72]. The details of these complex interactions are beyond the scope of the present study. However, we postulate that the splenocyte model more accurately replicates in vivo immune responses compared to reductionist models using a single immortalized or isolated cell line. Moreover, we can infer that IL-7 selectively restored the functions of TLR-9-responsive immature dendritic cells [e.g., to produce TNFα (Fig 7A)] and T cells (and consequently NK cells) [e.g., to produce IFNγ (Fig 7B)], and this effect may be related, in part, to changes in IRAK-M expression (Fig 9). Since IL-7 did not completely reverse tolerance or cross-tolerance, it is apparent that further studies are needed to consider other mechanisms, and related treatments, contributing to tolerance and cross-tolerance in response to acute TLR-4 or TLR-9 stimulation.

In summary, the profiles of tolerance and cross-tolerance following treatments with LPS or CpG DNA (TLR-4 and TLR-9 ligands, respectively) in a murine ex vivo splenocyte model are distinct. Tolerance and cross-tolerance to LPS was shown to be associated with dramatic and selective suppression of pro-inflammatory cytokines (TNFα, IFNγ); whereas, tolerance to CpGA DNA affected both pro- (TNFα, IFNγ) and anti-inflammatory (IL-10) cytokines. Additionally, CpG DNA was shown to prime the splenocytes to promote LPS-induced IL-10 release. The mechanisms of early immune tolerance in this model were unrelated to IL-10 or PD-1/PD-L1, and immune tolerance, particularly IFNγ suppression, was significantly reversed following treatment with IL-7. Furthermore, IL-7 did not promote IL-10 release. Together, these data demonstrate that IL-7 significantly reverses tolerance and cross-tolerance induced by LPS or CpG DNA, and to our knowledge, this is the first study to implicate IRAK-M as a target of IL-7-mediated activity. Thus, the murine splenocyte model, which closely replicates complex intercellular interactions in vivo, is shown to be useful for examining the mechanisms of tolerance and cross-tolerance consequent to exposure to bacterial or host danger signals, and for developing related treatment strategies, in the context of critical illness.

Supporting Information

S1 Checklist. The ARRIVE Guidelines Checklist provides direction as to where information related to the use of animals in the present study is located within the manuscript.

https://doi.org/10.1371/journal.pone.0132921.s001

(PDF)

S1 Fig. Post-experimental analyses of the side-scattered light (SSC) demonstrated minimal variability among the experimental groups following flow cytometry evaluation of treatment-induced increases in splenocyte PD-1/PD-L1 expression.

(A) Overlays of the various treatment groups demonstrated only minimal changes between Vehicle (Veh)/Non-treated (NT) versus treated groups. (B) Histogram of the mean SSC showing comparable SSC values for the NT-NT/Veh-Veh groups with an expected increase observed for the treated groups (LPS or CpG) typical of activated cell populations. (C) Detailed histogram statistics of the SSC signal confirmed similar SSC detection patterns in the NT-NT/Veh-Veh groups with slight increases in the mean and percentage of coefficient of variation of the SSC signal in the treated groups (LPS-LPS or CpGA-CpGA) consistent with the morphological changes expected with cell activation following treatment with pathogen-associated molecular patterns (PAMPs) like LPS and CpGA.

https://doi.org/10.1371/journal.pone.0132921.s002

(TIF)

Acknowledgments

The authors wish to thank Lucia E. Rosas, D.V.M., for all her help with additional post-experimental flow cytometry analyses related to cellular PD-1/PD-L1 expressions.

Author Contributions

Conceived and designed the experiments: MWJ MNB RSH TLP EDC. Performed the experiments: MWJ HRS. Analyzed the data: MWJ HRS TLP EDC. Contributed reagents/materials/analysis tools: MWJ MNB RSH TLP EDC. Wrote the paper: MWJ RSH EDC.

References

  1. 1. Dobrovolskaia MA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, et al. Induction of in vitro reprogramming by Toll-Like Receptor (TLR)2 and TLR4 agonists in murine macrophages: Effects of TLR “homotolerance” versus “heterotolerance” on NF-kappa B signaling pathway components. J Immunol. 2003; 170:508–519. pmid:12496438
  2. 2. Draisma A, Pickkers P, Bouw MP, van der Hoeven JG. Development of endotoxin tolerance in humans in vivo. Crit Care Med. 2009; 37:1261–1267. pmid:19242351
  3. 3. Castegren M, Skorup P, Lipcsey M, Larsson A, Sjolin J. Endotoxin tolerance variation over 24 h during porcine endotoxemia: association with changes in circulation and organ dysfunction. PLoS One. 2013; 8:e53221. pmid:23326400
  4. 4. Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, et al. Reversal of immunoparalysis in humans in vivo; a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012; 186:838–845. pmid:22822024
  5. 5. Dalpke AH, Lehner MD, Hartung T, Heeg K. Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology. 2005; 116:203–212. pmid:16162269
  6. 6. Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest. 2013; 123:2994–3001. pmid:23778142
  7. 7. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J Virology. 2007; 81:3170–3180. pmid:17229689
  8. 8. Sieben M, Schafer P, Dinsart C, Galle PR, Moehler M. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. Int J Cancer. 2013; 132:2548–2556. pmid:23151948
  9. 9. Boehme KW, Compton T. Innate sensing of viruses by Toll-like receptors. J Virology. 2004; 78:7867–7873. pmid:15254159
  10. 10. Iversen AC, Steinkjer B, Nilsen N, Bohnhorst J, Moen SH, Vik R, et al. A proviral role for CpG in cytomegalovirus infection. J Immunol. 2009; 182:5672–5681. pmid:19380814
  11. 11. Julian MW, Shao G, Bao S, Knoell DL, Papenfuss TL, VanGundy ZC, et al. Mitochondrial transcription factor A serves as a danger signal by augmenting plasmacytoid dendritic cell responses to DNA. J Immunol. 2012; 189:433–443. pmid:22675199
  12. 12. Yeo SJ, Yoon JG, Hong SC, Yi AK. CpG DNA induces self and cross-hyporesponsiveness of RAW264.7 cells in response to CpG DNA and lipopolysaccharide: alterations in IL-1 receptor-associated kinase expression. J Immunol. 2003; 170:1052–1061. pmid:12517973
  13. 13. van’t Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES, et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol. 2007; 179:7110–7120. pmid:17982103
  14. 14. Zhou H, Yu M, Fukuda K, Im J, Yao P, Cui W, et al. IRAK-M mediates Toll-like receptor/IL-1R-induced NFκB activation and cytokine production. EMBO J 2013; 32:583–596. pmid:23376919
  15. 15. Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med. 2014; 20:224–233. pmid:24485901
  16. 16. Kobayashi T, Matsuoka K, Sheikh SZ, Russo SM, Mishima Y, Collins C, et al. IL-10 regulates IL12b expression via histone deacetylation: implications for intestinal macrophage homeostasis. J Immunol. 2012; 189:1792–1799. pmid:22786766
  17. 17. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012; 10:544–555. pmid:22542159
  18. 18. Kroemer G, Cuende E, Martinez C. Compartmentalization of the peripheral immune system. Adv Immunol. 1993; 53:157–216. pmid:8512035
  19. 19. Cook CH. Cytomegalovirus reactivation in “immunocompetent” patients: A call for scientific prophylaxis. J Infect Dis. 2007; 196:1273–1275. pmid:17922387
  20. 20. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med. 2013; 187:1287–1293. pmid:23590272
  21. 21. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013; 13:862–874. pmid:24232462
  22. 22. Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: Is individualized immune-modulatory therapy the answer? Virulence. 2014; 5:45–56. pmid:24067565
  23. 23. Shindo Y, Unsinger J, Burnham CA, Green JM, Hotchkiss RS. Interleukin 7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock 2015; Jan 6 [Epub ahead of print].
  24. 24. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 2000; 60:3239–3246. pmid:10866317
  25. 25. Papenfuss TL, Kithcart AP, Powell ND, McClain MA, Gienapp IE, Shawler TM, et al. Disease-modifying capability of murine Flt3-ligand DCs in experimental autoimmune encephalomyelitis. J Leukoc Biol. 2007; 82:1510–1518. pmid:17855499
  26. 26. Julian MW, Shao G, VanGundy ZC, Papenfuss TL, Crouser ED. Mitochondrial transcription factor A, an endogenous danger signal, promotes TNFα release via RAGE- and TLR9-responsive plasmacytoid dendritic cells. PLoS One. 2013; 8:e72354. pmid:23951313
  27. 27. Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002; 110:191–202. pmid:12150927
  28. 28. Ballinger MN, Newstead MW, Zeng X, Bhan U, Horowitz JC, Moore BB, et al. TLR signaling prevents hyperoxia-induced lung injury by protecting alveolar epithelium from oxidant-mediated death. J Immunol. 2012; 189:356–364. pmid:22661086
  29. 29. Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Bank RE. Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics. 2005; 5:566–571. pmid:15627964
  30. 30. Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, et al. IL-7 restores lymphocyte functions in septic patients. J Immunol. 2012; 189:5073–5081. pmid:23053510
  31. 31. Koenen P, Heinzel S, Carrington EM, Happo L, Alexander WS, Zhang JG, et al. Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals. Nat Commun. 2013; 4:1735. pmid:23591902
  32. 32. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med. 1997; 25:1813–1819. pmid:9366763
  33. 33. Rixen D, Siegel JH, Friedman HP. “Sepsis/SIRS”, physiologic classification, severity stratification, relation to cytokine elaboration and outcome in posttrauma critical illness. J Trauma. 1996; 41:581–598. pmid:8858015
  34. 34. Xiong Y, Pennini M, Vogel SN, Medvedev AE. IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance. J Leukoc Biol. 2013; 94:291–300. pmid:23695305
  35. 35. Kawasaki T, Ogata M, Kawasaki C, Tomihisa T, Okamoto K, Shigematsu A. Surgical stress induces endotoxin hyporesponsiveness and an early decrease of monocyte mCD14 and HLA-DR expression during surgery. Anesth Analg. 2001; 92:1322–1326. pmid:11323370
  36. 36. Heagy W, Nieman K, Hansen C, Cohen M, Danielson D, West MA. Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surgical Infections. 2003; 4:171–180. pmid:12906717
  37. 37. Heagy W, Hansen C, Nieman K, Cohen M, Richardson C, Rodriguez JL, et al. Impaired ex vivo lipopolysaccharide-stimulated whole blood tumor necrosis factor production may identify “septic” intensive care unit patients. Shock. 2000; 14:271–276. pmid:11028542
  38. 38. Xiong Y, Medvedev AE. Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20. J Leukoc Biol. 2011; 90:1141–1148. pmid:21934070
  39. 39. O’Brien AD, Rosenstreich DL, Scher I, Campbell GH, MacDermott RP, Formal SB. Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J Immunol. 1980; 124:20–24. pmid:6985638
  40. 40. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Int Med. 2002; 162:1028–1032.
  41. 41. Weijer S, Lauw FN, Branger J, van den Blink B, van der Poll T. Diminished interferon-γ production and responsiveness after endotoxin administration to healthy humans. J Infect Dis. 2002; 186:1748–1753. pmid:12447760
  42. 42. Wurzel DF, Mackay IM, Marchant JM, Wang CY, Yerkovich ST, Upham JW, et al. Adenovirus species C is associated with chronic suppurative lung diseases in children. Clin Infect Dis. 2014; 59:34–40. pmid:24748519
  43. 43. Techasaensiri B, Techasaensiri C, Mejias A, McCracken GM Jr, Ramilo O. Viral coinfections in children with invasive pneumococcal disease. Pediatr Infect Dis J. 2010; 29:519–523. pmid:20051928
  44. 44. Zhou F, Ciric B, Li H, Yan Y, Li K, Cullimore M, et al. IL-10 deficiency blocks the ability of LPS to regulate expression of tolerance-related molecules on dendritic cells. Eur J Immunol. 2012; 42:1449–1458. pmid:22622800
  45. 45. Jiang HR, Muckersie E, Robertson M, Xu H, Liversidge J, Forrester JV. Secretion of interleukin-10 or interleukin-12 by LPS-activated dendritic cells is critically dependent on time of stimulus relative to initiation of purified DC culture. J Leukoc Biol. 2002; 72:978–985. pmid:12429720
  46. 46. Van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol. 2004; 172:7603–7609. pmid:15187140
  47. 47. Dolgachev VA, Yu B, Reinke JM, Raghavendran K, Hemmila MR. Host susceptibility to gram-negative pneumonia after lung contusion. J Trauma Acute Care Surg. 2012; 72:614–623. pmid:22491544
  48. 48. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10:826–837. pmid:21088683
  49. 49. Lee N, Wong CK, Hui DS, Lee SK, Wong RY, Ngai KL, et al. Role of human Toll-like receptors in naturally occurring influenza A infections. Influenza Other Respir Viruses. 2013; 7:666–675. pmid:23552014
  50. 50. Torcia MG, Nencioni L, Clemente AM, Civitelli L, Celestino I, Limongi D, et al. Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males. PLoS One. 2012; 7:e39853. pmid:22768144
  51. 51. Cho HY, Choi EK, Lee SW, Jung KO, Seo SK, Choi IW, et al. Programmed death-1 receptor negatively regulates LPS-mediated IL-12 production and differentiation of murine macrophage RAW264.7 cells. Immunol Lett. 2009; 127:39–47. pmid:19723542
  52. 52. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010; 14:R220. pmid:21118528
  53. 53. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014; 18:R3. pmid:24387680
  54. 54. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed cell death ligand-1 on monocytes in septic shock patients. Crit Care. 2011; 15:R70. pmid:21349174
  55. 55. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004; 173:945–954. pmid:15240681
  56. 56. Li L, Masucci MG, Levitsky V. Effect of interleukin-7 on the in vitro development and maturation of monocyte derived human dendritic cells. Scand J Immunol. 2000; 51:361–371. pmid:10736108
  57. 57. Miller ML, Mashayekhi M, Chen L, Zhou P, Liu X, Michelotti M, et al. Basal NF-κB controls IL-7 responsiveness of quiescent naïve T cells. Proc Natl Acad Sci USA 2014; 111:7397–7402. pmid:24799710
  58. 58. Nalos M, Santner-Nanan B, Parnell G, Tang B, McLean AS, Nanan R. Immune effects of interferon gamma in persistent staphylococcal sepsis. Am J Respir Crit Care Med. 2012; 185:110–112. pmid:22210794
  59. 59. Liu ZJ, Yan LN, Li XH, Xu FL, Chen XF, You HB, et al. Up-regulation of IRAK-M is essential for endotoxin tolerance induced by a low dose of lipopolysaccharide in Kupffer cells. J Surg Res. 2008; 150:34–39. pmid:18533191
  60. 60. Kim YI, Park JE, Martinez-Hernandez A, Yi AK. CpG DNA prevents liver injury and shock-mediated death by modulating expression of interleukin-1 receptor-associated kinases. J Biol Chem. 2008; 283:15258–15270. pmid:18378686
  61. 61. Nahid MA, Yao B, Dominquez-Gutierrez PR, Kesavalu L, Satoh M, Chan EK. Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212. J Immunol. 2013; 190:1250–1263. pmid:23264652
  62. 62. Nahid MA, Satoh M, Chan EK. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol. 2011; 186:1723–1734. pmid:21178010
  63. 63. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004; 21-227-239.
  64. 64. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002; 17:677–687. pmid:12433373
  65. 65. Parra M, Yang AL, Lim J, Kolibab K, Derrick S, Cadieux N, et al. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin Vaccine Immunol. 2009; 16:1025–1032. pmid:19458207
  66. 66. Turner DJ, Hoyle SL, Snewin VA, Gares MP, Brown IN, Young DB. An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis. Microbiology. 2002; 148:2929–2936. pmid:12368426
  67. 67. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, et al. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines. PNAS. 2002; 99:6181–6186. pmid:11972057
  68. 68. Ilyinskii PO, Wang R, Balk SP, Exley MA. CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMVC) in vitro and immune response to EMCV infection in vivo. J Virol. 2006; 80:7146–7158. pmid:16809320
  69. 69. Yue SC, Nowak M, Shaulov-Kask A, Wang R, Yue D, Balk SP, et al. Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol. 2010; 184:268–276. pmid:19949077
  70. 70. Guillerey C, Mouries J, Polo G, Doyen N, Law HK, Chan S, et al. Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice. Blood. 2012; 120:90–99. pmid:22611152
  71. 71. Perona-Wright G, Jenkins SJ, Crawford A, Gray D, Pearce EJ, MacDonald AS. Distinct sources and targets of IL-10 during dendritic cell-driven Th1 and Th2 responses in vivo. Eur J Immunol. 2006; 36:2367–2375. pmid:16917957
  72. 72. Souza-Fonseca-Guimaraes F, Parlato M, Fitting C, Cavaillon JM, Adib-Cunquy M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. J Immunol. 2012; 188:5850–5858. pmid:22566566